Display Settings:

Format

Send to:

Choose Destination
    Anticancer Res. 2004 Mar-Apr;24(2C):1187-92.

    Impact of mistletoe lectin binding in breast cancer.

    Source

    Zentrum für diagnostische Medizin Robert Bosch Krankenhaus, Auerbachstr. 110, D-70376 Stuttgart, Germany.

    Abstract

    BACKGROUND:

    One of the most often used complementary or alternative anticancer therapeutics for breast cancer is mistletoe extract with Viscum album lectin (VAA-1) as the leading component. The aim of this study was to determine the correlation between VAA-1 binding in breast cancer and disease outcome.

    MATERIALS AND METHODS:

    VAA-1 binding to either tumour cells or tumour infiltrating inflammatory cells was examined by immunohistochemical staining of paraffin tissue sections from breast cancer patients (n=226).

    RESULTS:

    About 34% of breast cancer tumour cells displayed a strong VAA-1 binding. Kaplan-Meier statistics revealed an inverse correlation between disease outcome and presence of strong VAA-1 binding to tumour cells.

    CONCLUSION:

    As binding of VAA-1 indicates the presence of galactose molecules in saccharide structures of the cytoplasm or cell membrane, we conclude that the amount of galactose-containing glycoproteins, mucoproteins and glycolipids in breast cancer tumour cells is related to disease outcome.

    PMID:
    15154645
    [PubMed - indexed for MEDLINE]

      Supplemental Content

      Icon for HighWire Press

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk